<DOC>
	<DOCNO>NCT02971007</DOCNO>
	<brief_summary>This multi-center , randomize study evaluate safety , tolerability , efficacy 200 mg CAMB 400 mg CAMB compare single 150 mg dose fluconazole treatment moderate severe VVC .</brief_summary>
	<brief_title>Safety Efficacy Oral Encochleated Amphotericin B ( CAMB/MAT2203 ) Treatment Vulvovaginal Candidiasis ( VVC )</brief_title>
	<detailed_description>This multi-center , randomize study evaluate safety , tolerability , efficacy 200 mg CAMB 400 mg CAMB compare single 150 mg dose fluconazole treatment moderate severe VVC . Approximately 75 woman moderate severe VVC randomize 1 3 treatment group ( 200 mg CAMB , 400 mg CAMB , fluconazole ) achieve approximately 25 subject group . The primary objective study evaluate safety 200 mg 400 mg dos oral CAMB 5 day compare single 150 mg dose oral fluconazole subject moderate severe VVC . The secondary efficacy objective study include clinical cure rate , mycology eradication responder outcome . Tertiary objective include pharmacokinetics .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Vulvovaginitis</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Key Informed consent Clinical diagnosis moderate severe VVC Negative pregnancy test Vaginal pH le 4.5 Key Has intolerance hypersensitivity amphotericin B ( AMB ) product , azole antifungal drug Receiving antifungal therapy unrelated VVC evidence systemic fungal infection require antifungal therapy Has receive treatment VVC within past 30 day experience 4 episode VVC past 12 month Has another cause vulvovaginitis Has urogenital infection ( ) would potentially alter response disease Has another vaginal vulvar condition would confound interpretation clinical response Has significant laboratory abnormality screening Has know azoleresistant Candida infection ; Has condition Investigator believe would interfere subject 's ability provide inform consent , comply study instruction , put subject undue risk</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>